Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg

Herrschaft, H.; Nacu, Anatol; Sa, Likhachev; Sholomov, I. I.; Hoerr, Robert; Schlaefke, Sandra

doi:10.1016/j.jpsychires.2012.03.003

Cited by 158 publications

(156 citation statements)

References 41 publications

Supporting

Mentioning

152

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, a multicenter, double-blind, randomized study was conducted to demonstrate the effectiveness of Ginkgo biloba (240 mg/day) compared to placebo in 410 patients with mildmoderate dementia (vascular dementia or Alzheimer's disease) for 24 weeks. The results showed a benefit of using Ginkgo biloba compared to placebo in cognition, psychopathology, functional measures and quality of life for patients and caragivers [233].…”

Section: Egb 761 (Ginkgo Biloba)mentioning

confidence: 95%

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Alvarado¹,

Brito²,

Román³

et al. 2017

J Neurol Neurosci

View full text Add to dashboard Cite

Cerebral vascular disease (CVD) represents the second cause in years of life lost, according to the Global Burden of Disease Study 2015 study. The global report on Alzheimer's disease 2015 estimates that in Latin America there are 9.2 million cases of dementia, with a prevalence of 8.2%. Undoubtedly, Alzheimer's disease is the most frequent cause, followed by vascular dementia (VD) with 15% of the cases, although global data are unknown in Latin America. Objective:To analyze and present the current evidence on the classification, pathophysiology, diagnosis and treatment of vascular cognitive impairment. Methodology:A group of experts met in Miami, Florida, in April 2016. The group included Neurologists, Geriatricians and Psychiatrists from the following countries: Mexico, Guatemala, El Salvador, Costa Rica, Peru, Spain, Bolivia, Chile, Paraguay, Colombia, Panama, Venezuela, Italy, the United States, Dominican Republic, Honduras and Nicaragua. The Delphi method was used to review available information (provided months before the meeting), in relation to assigned topics: definition of Cognitive Vascular Impairment (CVI), risk factors, pathophysiology, diagnosis (neuropsychological and imaging) and treatment. For the allocation of evidence and recommendation of available treatments, the GRADE system was used.The working groups analyzed and discussed available evidence on CVI concerning proposed definitions, risk factors and diagnostic elements. Subsequently, the conclusions of each of the working groups were drafted, which were reviewed by each of the authors and by the rest of the study groups until a global consensus was reached. Once this process was completed, the process of external validation and preparation of the final document was carried out.The results of this consensus allow the incorporation of the opinion and experience of physicians of different specialties in Latin America regarding the vascular cognitive impairment.

show abstract

Section: Egb 761 (Ginkgo Biloba)mentioning

confidence: 95%

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Alvarado¹,

Brito²,

Román³

et al. 2017

J Neurol Neurosci

View full text Add to dashboard Cite

show abstract

“…The randomized, placebo-controlled, double-blind, multicenter, parallel-group trial was performed in accordance with the provisions for Good Clinical Practice set by the International Conference on 8 Briefly, we enrolled patients with mild to moderate dementia (AD, VaD or AD with cerebrovascular disease) who scored 35 or less in the Test for the Early Detection of Dementia with Differentiation from Depression 10 and 9 to 23 on the SKT short cognitive performance test 11 and had clinically significant NPS, evidenced by a composite score of at least 6 on the Neuropsychiatric Inventory (NPI), 12 with at least one item score (other than delusions or hallucinations) of at least 4 Changes from baseline in the SKT and NPI total scores were defined prospectively as primary outcome measures. Changes from baseline to week 24 in NPI caregiver distress and in all single items of the NPI were specified as secondary outcomes.…”

Section: Methodsmentioning

confidence: 99%

“…Details of the statistical analysis are described elsewhere. 8 The changes of the composite and caregiver distress scores of the single NPI items between baseline and week 24 were compared between the treatment groups using twosided Student's t-tests.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial

Nacu¹,

Hoerr²

2016

OAJCT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, it was found to be safe and effective in a multi-center, double-blind, randomized, placebo-controlled, 24-week trial with 410 outpatients [64]. Recently, a study assesses the association between intake of EGb761 and cognitive function of elderly adults over a 20-year period and reported that cognitive decline was lower in the subjects using EGb761 [65].…”

Section: Ginkgo Bilobamentioning

confidence: 99%

Traditional Korean East Asian Medicines and Herbal Formulations for Cognitive Impairment

Kumar

Song

et al. 2013

Molecules

View full text Add to dashboard Cite

Abstract:Hanbang, the Traditional Korean Medicine (TKM), is an inseparable component of Korean culture both within the country, and further afield. Korean traditional herbs have been used medicinally to treat sickness and injury for thousands of years. Oriental medicine reflects our ancestor's wisdom and experience, and as the elderly population in Korea is rapidly increasing, so is the importance of their health problems. The proportion of the population who are over 65 years of age is expected to increase to 24.3% by 2031. Cognitive impairment is common with increasing age, and efforts are made to retain and restore the cognition ability of the elderly. Herbal materials have been considered for this purpose because of their low adverse effects and their cognitive-enhancing or anti-dementia activities. Herbal materials are reported to contain several active compounds that have effects on cognitive function. Here, we enumerate evidence linking TKMs which have shown benefits in memory improvements. Moreover, we have also listed Korean herbal formulations which have been the subject of scientific reports relating to memory improvement.

show abstract

Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg

Cited by 158 publications

References 41 publications

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial

Traditional Korean East Asian Medicines and Herbal Formulations for Cognitive Impairment

Contact Info

Product

Resources

About

Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg

Cited by 158 publications

References 41 publications

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Latin American Delphi Consensus on Vascular Cognitive Impairment: Definitions, Clinical Features, Pathophysiology, Prevention and Treatment

Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761&reg; treatment: additional results from a 24-week randomized, placebo-controlled trial

Traditional Korean East Asian Medicines and Herbal Formulations for Cognitive Impairment

Contact Info

Product

Resources

About

Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: additional results from a 24-week randomized, placebo-controlled trial